This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Early Detection of Cognitive Dysfunction in Diabetes

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by zhipeng xu, Wuhan General Hospital of Guangzhou Military Command.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
zhipeng xu, Wuhan General Hospital of Guangzhou Military Command
ClinicalTrials.gov Identifier:
NCT01830998
First received: April 1, 2013
Last updated: December 9, 2014
Last verified: December 2014
April 1, 2013
December 9, 2014
January 2012
December 2014   (Final data collection date for primary outcome measure)
MMSE Olfactory function dementia [ Time Frame: 2 years ]
MMSE,Olfactory function and PET(fMRI) were observed.
Same as current
Complete list of historical versions of study NCT01830998 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Early Detection of Cognitive Dysfunction in Diabetes
Study of Cognitive Dysfunction and Diabetes
The rate of cognitive decline due to ageing is increased 1.5-fold to 2.0-fold in individuals with type 2 diabetes.There are no established specific treatment measures to prevent or ameliorate cognitive impairments in patients with diabetes. we want to detecte early clinical dementia in diabete.
Clinically relevant cognitive decrements in relation to diabetes mainly occur during two crucial periods in life: the period of brain development in childhood, and the period when the brain undergoes neurodegenerative changes associated with ageing.Potential leads for treatment are to optimise glycaemic control and avoid and treat vascular risk factors.we want to detecte early clinical dementia in diabete by MMSE and Olfactory function.
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   None Retained
Description:
serum
Probability Sample
Patients with type 2 diabetes
  • Dementia
  • DM
  • MCI
Not Provided
  • control,MCI, Olfactory dsfunction
    There are different groups:control,MCI, Olfactory dsfunction.
  • control, MCI
    control and MCI group.Glycaemic control
  • control and MCI
    treatment and without treatment
  • MCI and Olfactory function
    observation between MCI and Olfactory function groups.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
400
December 2014
December 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with type 2 diabetes(Age>50 years)

Exclusion Criteria:

  • with stroke or other complications.
Sexes Eligible for Study: All
50 Years to 80 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT01830998
20130401
No
Not Provided
Not Provided
Not Provided
zhipeng xu, Wuhan General Hospital of Guangzhou Military Command
Wuhan General Hospital of Guangzhou Military Command
Not Provided
Not Provided
Wuhan General Hospital of Guangzhou Military Command
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP